An observational study in Obesity & Overweight, sponsored by Université Catholique de Louvain. Recruiting at 1 site in Belgium. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-14.
Sponsored by Université Catholique de Louvain · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 133 studies in Obesity with a site in Belgium — 40 open to participants now, 56 under way, 22 of them phase 3. Obesity · Belgium.
Among the 133 studies in Obesity with a site in Belgium, this one is the 19th largest by planned enrollment of the 35 observational ones that give a count, is one of 16 that started in 2026, is one of 35 observational ones, reaches primary completion later than 52 of the 55 other live ones, and was the 120th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →40 of the 133 studies in Obesity with a site in Belgium are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Belgium, United States, Israel and 7 more countries
Ages 6–11
Universitaire Ziekenhuizen KU Leuven · Sites in Belgium
Ages 18–65
Novo Nordisk A/S · Sites in Belgium, United States, Bulgaria and 7 more countries
Ages 18+
Novo Nordisk A/S · Sites in Belgium, United States, Argentina and 16 more countries
Ages 18+
Hoffmann-La Roche · Sites in Belgium, United States, Argentina and 18 more countries
Ages 18+
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
133 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 37 · Phase 4 10
First in 2001; this study’s year is marked. 16 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 115 across 2,159 observational studies indexed under Obesity.
Median enrollment 200 across the 97 interventional studies, 150 across the 35 observational. Of the 65 that completed or were terminated, 15 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
61 of 133 have an industry lead sponsor. The 10 most frequent:
Université Catholique de Louvain is the lead sponsor of 155 studies on the registry; 60 are open to participants now.
Université Catholique de Louvain has 2 studies filed under Obesity — fewer than ten, so there is no comparison to draw.
9 of the studies in Obesity with a site in Belgium that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06858839Phase 3AmgenEvaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06672549Phase 3Eli Lilly and CompanyA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | 2027-02 |
| NCT05556512Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity | 2027-10 |
| NCT07145671Universiteit AntwerpenThe COCCOS Study: a Transition Program for Young Persons With Chronic Conditions | 2026-12 |
| NCT05315752Centre Hospitalier Universitaire Saint PierreChanges in Body Fat and Morphologic Characteristics Associated With OSA Resolution After Bariatric Surgery | 2026-12-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 133 studies in Obesity with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
As with other nutritional strategies, the clinical response to bariatric surgery can be highly variable, with weight regain being a frequent occurrence. Recent evidence on anti-obesity medication indicate similar inter-individual variability in clinical response. Among multiples factors, co-occurrence of eating disorders such as binge eating disorder has been implicated in insufficient clinical response. Improving our ability to predict how patients will respond to obesity treatment is necessary in order to tailor the care pathways we offer. The mechanisms involved in disturbances of eating behaviour before and after surgery remain largely unknown. This study aims to identify the predictive factors of weight loss after pharmacological or surgical treatment, as well as the cognitive and biological mechanisms that mediate this effect.
Participants initiating an anti-obesity medication or candidates for bariatric surgery once its indication has been validated by a multidisciplinary committee, following medical, nutritional and psychological evaluations.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Longitudinal follow-up of participants who initiate an anti-obesity medication or whose application for bariatric surgery was accepted. It will combine anthropometric, clinical, neuropsychological and biological measurements taken at various timepoints. Participants will be asked to complete a set of online questionnaires and data will be recorded anonymously. Biological samples will be collected at various time points.
Correlation between weight loss after treatment and clinical, neuropsychological and biological parameters.
The percentage of excessive weight loss after treatment will be correlated with * Clinical parameters (Binge Eating Scale and modified Yale Food Addiction Scale 2.0) * Neuropsychological parameter (Barratt Impulsivness Scale and Trail Making Test) * Biological parameters
Time frame: Throughout the entire study, aproximately during 5 years
Binge Eating Disorder.
Evaluation of eating disorders using the Binge Eating Scale (BES).
Time frame: Throughout the entire study, aproximately during 5 years
Food Addiction.
Evaluation of food addiction will be performed using modified Yale Food Addiction Scale 2.0.
Time frame: Throughout the entire study, aproximately during 5 years
Eating attitudes
Eating patterns and habits will be screened using the Eating Attitude Test 26
Time frame: Throughout the entire study, aproximately during 5 years
Cognitive flexibility.
Neuropsychological evaluation of cognitive flexibility will be performed with the Trail Making Test
Time frame: Throughout the entire study, aproximately during 5 years
Impulsivity.
Impulsivity will be assessed using the Barrat Impulsiveness Scale (BIS)
Time frame: Throughout the entire study, aproximately during 5 years
Self-reported quality of life.
Self-reported quality of life will be assessed using the QOLOD (Quality of Life, Obesity and Dietetics)
Time frame: Throughout the entire study, aproximately during 5 years
Obesity.
Weight will be measured at each timepoint
Time frame: Throughout the entire study, aproximately during 5 years
Physical activity.
Weekly physical activity will be reported with the Godin Leisure Time Exercise Questionnaire (GLTEQ)
Time frame: Throughout the entire study, aproximately during 5 years
Food intake.
Eating habits will be recorded with a Food Frequency Questionnaire (FFQ)
Time frame: Throughout the entire study, aproximately during 5 years
Blood samples
Blood samples will be collected and processed for metabolomic analyses.
Time frame: Throughout the entire study, aproximately during 5 years
Fecal sample
Feces samples will be collected and processed to evaluation gut-microbiota composition
Time frame: Throughout the entire study, aproximately during 5 years
Sociodemographic data
Number of children and marital status will be recorded
Time frame: Once at inclusion
Medical history
Information concerning medical comorbidities will be collected from the patient medical record.
Time frame: Once at inclusion
Childhood Trauma.
Assessment of adverse life events and trauma will used the Childhood Trauma Questionnaire - short form.
Time frame: Once at inclusion
Plan to share: No
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for Jun 2032, 73 months after the start.
Of 796 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's planned 73 months is above that.
Counting every sponsor, half of 842 studies reached it within 39 months; a quarter within 17 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Université Catholique de Louvain →